New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
13:30 EDTPRGOPerrigo confirms FDA approval of testosterone gel 1%
Perrigo Company (PRGO) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%. AndroGel 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705M annually, as measured by Symphony Health. Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTPRGOPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:53 EDTPRGOPerrigo announces launch of generic version of Astellas' Protopic ointment
Perrigo announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic Ointment is indicated to treat moderate to severe eczema. Brand sales were approximately $176M over the last 52 weeks according to Symphony Health Solutions.
November 21, 2014
14:17 EDTPRGOPerrigo price target raised to $184 from $175 at CRT Capital
Subscribe for More Information
10:20 EDTPRGOHigh option volume stocks
Subscribe for More Information
November 20, 2014
20:07 EDTPRGOPerrigo 5.92M share Secondary priced at $152.00
Subscribe for More Information
10:33 EDTPRGOHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
06:56 EDTPRGOPerrigo files to sell $900M in ordinary shares
Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition of Omega Pharma Invest NV and to repay or refinance certain indebtedness of Perrigo and/or Omega. If the Acquisition is not consummated, then the net proceeds of the offering will be used for general corporate purposes. J.P. Morgan, Barclays and BofA Merrill Lynch are the joint book-running managers in the offering.
06:56 EDTPRGOPerrigo files automatic mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use